GSK (FKA GLAXOSMITHKLINE INC.) for GSK (FKA GLAXOSMITHKLINE INC.)

Health Issues HCR

H.R. 447: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation ___ H.R. 478: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation ___ H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems ___ H.R. 985: FAST Generics Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 1922/S. 1089 _ Restoring Access to Medicine Act ___ H.R. 1093: Stop Price Gouging Act - Provisions related to prescription drug pricing ___ H.R. 1332: Fair Care Act of 2019 - Provisions related to prescription drug pricing, patent issues, Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems ___ H.R. 1409: Transparency in All Health Care Pricing Act of 2019 - Provisions related to prescription drug pricing transparency ___ H.R. 1506: Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 1973: Vaccine Access Improvement Act ___ H.R. 2011: Protecting Access to Biosimilars Act of 2019 - Provisions related to biological products ___ H.R. 2038: State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019 - Provisions related to prescription drug pricing ___ H.R. 2064: To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes - Provisions related to prescription drug samples ___ H.R. 2069: Stopping the Pharmaceutical Industry from Keeping Drug Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs ___ H.R. 2087: Drug Price Transparency Act - Provisions related to prescription drug pricing and transparency ___ H.R. 2113: Prescription Drug STAR Act - Provisions related to prescription drug pricing, reporting and product samples ___ H.R. 2115: Public Disclosure of Drug Discounts Act - Provisions related to prescription drug pricing transparency and pharmacy benefit managers ___ H.R. 2296: FAIR Drug Pricing Act of 2019 / More Efficient Tools to Realize Information for Consumers Act - Provisions related to prescription drug pricing and transparency ___ H.R. 2376: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers ___ H.R. 2401: American Cures Act - Provisions related to pharmaceutical research and development ___ H.R. 3223: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers ___ H.R. 3327: Drug Price Transparency for Medicare Patients Act of 2019 - Provisions related to direct-to-consumer prescription drug advertising ___ H.R. 3415: Real-Time Beneficiary Drug Cost Bill - Provisions related to drug pricing transparency ___ H.R. 3443: Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 - Provisions related to FDA over-the-counter drug approvals ___ H.R. 3947: Competition Prescription Act of 2019 - Provisions related to prescription drug pricing, patents, and other provisions ___ H.R. 4106: Responsibility in Drug Advertising Act of 2019 - Provisions related to direct-to-consumer prescription drug advertising ___ H.R. 4158: CURE High Drug Prices Act - Provisions related to prescription drug pricing and transparency ___ H.R. 4538: To amend title III of the Public Health Service Act to limit the orphan drug exclusion under the drug discount program under section 340B of such title. - Provisions related to 340B prescription drug exclusions ___ S. 61: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation ___ S. 73: End Taxpayer Subsidies for Drug Ads Act - Provisions related to direct-to-consumer prescription drug advertising ___ S. 97: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation ___ S. 340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems ___ S. 378: Stop Price Gouging Act - Provisions related to prescription drug pricing ___ S. 440: PACED Act - Provisions related to use of sovereign immunity in patent disputes ___ S. 474: Stopping the Pharmaceutical Industry from Keeping Drug Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs ___ S. 637: Combatting Unreasonable Rises and Excessively (CURE) High Drug Prices Act - Provisions related to prescription drug pricing and transparency ___ S. 657: Drug Price Transparency Act - Provisions related to prescription drug pricing transparency and commercial market rebates ___ S. 658: Accelerated Drug Approval for Prescription Therapies Act - Provisions related to FDA drug approvals ___ S. 660: Efficiency and Transparency in Petitions Act - Provisions related to the FDA citizen petition process ___ S. 844: Short on Competition Act - Provisions related to generic prescription drug approvals and importation ___ S. 977: Transparent Drug Pricing Act of 2019 - Provisions related to pharmaceutical drug pricing ___ S. 1140: Protecting Access to Biosimilars Act of 2019 - Provisions related to biological products ___ S. 1227: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers ___ S. 1384: Prescription Drug Rebate Reform Act of 2019 - Provisions related to prescription drug pricing and commercial rebates ___ S. 1391: FAIR Drug Pricing Act of 2019 - Provisions related to prescription drug pricing and transparency ___ S. 1437: Drug-price Transparency in Communications (DTC) Act - Provisions related to direct-to-consumer prescription drug advertising ___ S. 1532: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers ___ S. 1664: Prescription Drug Price Reporting Act - Provisions related to prescription drug pricing transparency S.1872 _ Protecting Seniors through Immunizations Act of 2019 ___ S. 2387: We Protect American Investment in Drugs Act - Provisions related to prescription drug pricing ___ Transparency policy issues ___ Drug cost and pricing policy issues ___ Drug importation and counterfeiting policy issues ___ HHS Safe Importation Action Plan ___ Prescription drug take back and secure disposal policy issues ___ Policy issues related to prescription drug abuse and opioids ___ Expanded access policy issues ___ Generic drug approval process policy issues ___ High deductible health plans/HSA policy issues ___ Sharing of truthful and non-misleading information about medicines with healthcare professionals and payors ___ Risk Evaluation and Mitigation Strategy (REMS) policy issues ___ FDA modernization policy issues ___ PDUFA implementation policy issues ___ 340B drug discount program policy issues ___ Bipartisan Budget Act of 2018 (Public Law 115-123) - Part D provisions ___ Patient assistance program policy issues ___ Biosimilar approval and reimbursement policy issues ___ Cancer drug vial size policy issues ___ TRICARE pharmacy pilot program ___ Drug shortages policy issues ___ Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs (RIN 0991-ZA49)

Contacted: Patent & Trademark Office (PTO); U.S. Trade Representative (USTR); SENATE; Defense, Dept of (DOD); Centers For Medicare and Medicaid Services (CMS); Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Bills named: H.R. 3415 (116th), S. 658 (116th), S. 660 (116th), S. 657 (116th), H.R. 3443 (116th), S. 340 (116th), S. 1227 (116th), H.R. 2011 (116th), S. 1437 (116th), H.R. 2296 (116th), S. 977 (116th), H.R. 985 (116th), S. 474 (116th), H.R. 3947 (116th), H.R. 4538 (116th), S. 1872 (116th), H.R. 1922 (116th), H.R. 2376 (116th), H.R. 2115 (116th), H.R. 1973 (116th), H.R. 1409 (116th), H.R. 1506 (116th), H.R. 4158 (116th), S. 1391 (116th), S. 844 (116th), H.R. 3327 (116th), H.R. 2069 (116th), S. 1384 (116th), H.R. 1332 (116th), H.R. 2064 (116th), S. 1140 (116th), S. 1664 (116th), S. 637 (116th), S. 2387 (116th), S. 97 (116th), H.R. 2401 (116th), S. 61 (116th), S. 73 (116th), S. 378 (116th), H.R. 2087 (116th), H.R. 4106 (116th), H.R. 965 (116th), H.R. 2038 (116th), S. 440 (116th), H.R. 447 (116th), H.R. 1093 (116th), H.R. 2113 (116th), H.R. 3223 (116th), S. 1532 (116th), S. 1089 (116th), H.R. 478 (116th)

Medicare/Medicaid MMM

___ H.R. 3: Lower Drug Costs Now Act of 2019 - Provisions related to prescription drug pricing, foreign reference pricing, Part D, manufacturer rebates, and other provisions ___ H.R. 107: To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs - Provisions related to Medicaid drug rebates ___ H.R. 275: Medicare Prescription Drug Price Negotiation Act of 2019 - Provisions related to Part D and drug pricing negotiation ___ H.R. 448: Medicare Drug Price Negotiation Act - Provisions related to Part D and drug pricing negotiation ___ H.R. 937: Right Rebate Act of 2019 - Provisions related to Medicaid drug rebates and drug classification ___ H.R. 1034: Phair Pricing Act of 2019 - Provisions related to Part D and manufacturer rebates ___ H.R. 1035: Prescription Drug Price Transparency Act - Provisions related to drug pricing transparency and pharmacy benefit managers ___ H.R. 1046: Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Part D, drug pricing negotiation and compulsory licensing ___ H.R. 1346: Medicare Buy-In and Health Care Stabilization Act of 2019 - Provisions related to Part D and drug pricing negotiation ___ H.R. 1384: Medicare for All Act of 2019 - Provisions related to Part D, drug pricing negotiation and march-in rights ___ H.R. 1839: Medicaid Services Investment and Accountability Act - Provisions related to Medicaid drug rebates and drug classification ___ H.R. 2000: Medicare-X Choice Act of 2019 - Provisions related to Part D and drug pricing negotiation ___ H.R. 2452: Medicare for America Act of 2019 - Provisions related to Part D and drug pricing negotiation ___ H.R. 2463: Choose Medicare Act - Provisions related to Part D and drug pricing negotiation ___ H.R. 2757: Creating Lower cost Alternative for Your prescription drugs Act - Provisions related to Part D and patient cost-sharing ___ H.R. 3029: Improving Low-Income Access to Prescription Drugs Act of 2019 - Provisions related to Part D prescription drug plans ___ H.R. 3523: End Price Gouging for Medications Act - Provisions related to prescription drug pricing and foreign reference pricing ___ H.R. 3910: Equality in Medicare and Medicaid Treatment Act of 2019 - Provisions related to CMMI models ___ S. 62: Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 - Provisions related to Part D and drug pricing negotiation ___ S. 99: Medicare Drug Price Negotiation Act - Provisions related to Part D and drug pricing negotiation ___ S. 205: Right Rebate Act of 2019 - Provisions related to Medicaid drug rebates and drug classification ___ S. 377: Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Part D, drug pricing negotiation and compulsory licensing ___ S. 475: Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCap) Act of 2019 - Provisions related to Part D and patient cost-sharing ___ S. 470: Medicare at 50 Act - Provisions related to Part D and drug pricing negotiation ___ S. 476: Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 - Provisions related to transparency of prescription drug pricing and pharmacy benefit managers ___ S. 640: Phair Pricing Act of 2019 - Provisions related to Part D and manufacturer rebates ___ S. 691: Medicare Extra Rx Higher Eligibility Limits in Part D Act of 2019 - Provisions related to Part D and patient out-of-pocket costs ___ S. 801: Payment Commission Data Act - Provisions related to prescription drug pricing transparency and reporting ___ S. 981: Medicare-X Choice Act of 2019 - Provisions related to Part D and drug pricing negotiation ___ S. 1129: Medicare for All Act of 2019 - Provisions related to Part D and drug pricing negotiation ___ S. 1261: Choose Medicare Act - Provisions related to Part D and drug pricing negotiation ___ S. 1497: Health Care Price Check Act of 2019 - Provisions related to Medicare pricing transparency ___ S. 1785: Fair AMP Act - Provisions related to Medicaid drug rebates ___ S. 1801: Affordable Medications Act - Provisions relate to Part D drug pricing negotiation, importation, IP issues and pricing transparency ___ S. 1895: Lowering Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues ___ S. 1897: A bill to establish a process for updating the labeling of certain drugs with outdated labeling - Provisions related to prescription drug labeling ___ S. 1987: End Price Gouging for Medications Act - Provisions related to prescription drug pricing and foreign reference pricing ___ S. 1999: Improving Low-Income Access to Prescription Drugs Act of 2019 - Provisions related to Part D prescription drug plans ___ S. 2051: Strengthening Average Sales Price Reporting Act - Provisions related to Medicare pricing transparency and rebates ___ S. 2081: Stop Drug Companies from Overcharging Seniors in Medicare Part B Act of 2019 - Provisions related to prescription drug pricing and manufacturer rebates ___ S. 2247: Phair Pricing Act of 2019 - Provisions related to Part D and manufacturer rebates ___ S. 2252: Empowering States to Address Drug Costs Act - Provisions related to prescription drug pricing transparency ___ S. 2543: Prescription Drug Pricing Reduction Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions ___ Medicare Access and Childrens Health Insurance Program (CHIP) reauthorization policy issues ___ Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues ___ Part D policy issues including non-interference and rebates policy issues ___ Part B reform including MedPAC recommendations and other policy issues and local coverage decisions ___ Drug cost and pricing policy issues ___ Transparency policy issues ___ Alternative payment models policy issues ___ Value-based purchasing arrangements policy issues ___ Anti-Kickback Statute policy issues ___ Center for Medicare and Medicaid Innovation (CMMI) policy issues ___ Medicaid rebates and waiver policy issues ___ Prescription drug abuse policy issues ___ ANPRM; Medicare Program; International Pricing Index Model for Medicare Part B Drugs (CMS-5528-ANPRM) ___ Proposed Rule; Medicare and Medicaid Programs; Regulation To Require Drug Pricing Transparency (CMS-4187-P) ___ Proposed Rule; Contract Year (CY) 2020 Medicare Advantage and Part D Drug Pricing (CMS-4180-P) ___ Request for Information: Medicare and State Health Care Programs: Fraud and Abuse; Request for Information Regarding the Anti-Kickback Statute and Beneficiary Inducements CMP; 83 Fed. Reg. 43607 (Aug. 27, 2018) ___ Removal of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection (RIN 0936-AA08) Monograph Reform and HSA/FSAs

Contacted: Health & Human Services, Dept of (HHS); Patent & Trademark Office (PTO); Centers For Medicare and Medicaid Services (CMS); SENATE; Defense, Dept of (DOD); Office of Management & Budget (OMB); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES

Bills named: H.R. 448 (116th), S. 2252 (116th), S. 1999 (116th), H.R. 1046 (116th), S. 691 (116th), H.R. 3 (116th), H.R. 3910 (116th), S. 981 (116th), H.R. 2463 (116th), S. 377 (116th), S. 476 (116th), H.R. 107 (116th), S. 1895 (116th), H.R. 1839 (116th), S. 1497 (116th), S. 1785 (116th), S. 1801 (116th), H.R. 1384 (116th), H.R. 3523 (116th), H.R. 1034 (116th), H.R. 937 (116th), S. 470 (116th), H.R. 1035 (116th), S. 2247 (116th), S. 1261 (116th), S. 801 (116th), H.R. 2000 (116th), S. 1897 (116th), S. 205 (116th), H.R. 2452 (116th), S. 2081 (116th), S. 475 (116th), S. 1129 (116th), S. 640 (116th), H.R. 3029 (116th), S. 2543 (116th), H.R. 1346 (116th), S. 99 (116th), H.R. 275 (116th), S. 2051 (116th), S. 1987 (116th), S. 62 (116th), H.R. 2757 (116th)

Copyright/Patent/Trademark CPT

H.R. 465: Prescription Drug Price Relief Act of 2019 - Provisions related to foreign reference pricing, patents and march-in rights H.R. 938: BLOCKING Act of 2019 - Provisions related to 180 day generic prescription drug exclusivity H.R. 987: Strengthening Health Care and Lowering Prescription Drug Costs Act - Provisions related to prescription drug patent issues H.R. 990: Hatch-Waxman Integrity Act of 2019 - Provisions related to PTAB proceedings and other patent system reforms H.R. 1188: FLAT Prices Act - Provisions related to prescription drug patents, exclusivity periods and pricing H.R. 1499: Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements H.R. 1503: Orange Book Transparency Act - Provisions related to prescription drug and device patent listings H.R. 1520: Purple Book Continuity Act of 2019 - Provisions related to prescription drug patent listings ___ H.R. 2374: Stop STALLING Act - Provisions related to citizen petitions ___ H.R. 2375: Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements ___ H.R. 2387: STOP GAMES Act of 2019 - Provisions related to citizen petitions ___ H.R. 2455: Ensuring Timely Access to Generics Act of 2019 - Provisions related to citizen petitions ___ H.R. 2700: Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act - Provisions related to patent settlements, generic exclusivity, Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems ___ H.R. 3199: Terminating the Extension of Rights Misappropriated Act of 2019 - Provisions related to prescription drug patents ___ H.R. 3666: STRONGER Patents Act of 2019 - Provisions related to prescription drug patents ___ H.R. 4398: Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 - Provisions related to prescription drug patents ___ S. 64: Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements ___ S. 102: Prescription Drug Price Relief Act of 2019 - Provisions related to foreign reference pricing, patents and march-in rights ___ S. 344: Hatch-Waxman Integrity Act of 2019 - Provisions related to PTAB proceedings and other patent system reforms ___ S. 366: FLAT Prices Act - Provisions related to prescription drug patents, exclusivity periods and pricing ___ S. 659: Biologic Patent Transparency Act - Provisions related to prescription drug patent disclosures ___ S. 1169: Ensuring Timely Access to Generics Act of 2019 - Provisions related to citizen petitions ___ S. 1209: Reforming Evergreening and Manipulation that Extends Drug Years Act - Provisions related to prescription drug patents ___ S. 1224: Stop STALLING Act - Provisions related to citizen petitions ___ S. 1416: Affordable Prescriptions for Patients Act of 2019 - Provisions related to prescription drug patents ___ S. 1617: Second Look at Drug Patents Act of 2019 - Provisions related to prescription drug patents ___ S. 1636: Ensuring Innovation Act - Provisions related to new chemical exclusivity ___ S. 2082: STRONGER Patents Act of 2019 - Provisions related to prescription drug patents ___ Biopharmaceutical innovation and patent policy issues ___ Patent litigation reform issues and issues related to post-grant proceeding at the PTO ___ Bayh-Dole march-in rights policy issues

Contacted: SENATE; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Defense, Dept of (DOD); Office of Management & Budget (OMB); U.S. Trade Representative (USTR); Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES

Bills named: H.R. 938 (116th), S. 1416 (116th), H.R. 2700 (116th), S. 1209 (116th), H.R. 1499 (116th), H.R. 465 (116th), S. 1636 (116th), H.R. 3666 (116th), S. 659 (116th), S. 366 (116th), H.R. 1503 (116th), S. 2082 (116th), S. 1169 (116th), S. 64 (116th), H.R. 2374 (116th), H.R. 4398 (116th), H.R. 2375 (116th), S. 1617 (116th), S. 344 (116th), S. 102 (116th), H.R. 1188 (116th), H.R. 1520 (116th), H.R. 987 (116th), H.R. 990 (116th), H.R. 3199 (116th), H.R. 2387 (116th), H.R. 2455 (116th), S. 1224 (116th)

Trade (domestic/foreign) TRD

___ H.R. 2209: Fixing Global Freeloading Act - Provisions related to trade policy issues and international pharmaceutical drug pricing issues ___ Trade Agreements including NAFTA, USMCA and related policy issues ___ Biopharmaceutical innovation policy issues ___ International intellectual property and market access policy issues ___ Pricing and reimbursement policy issues

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); Defense, Dept of (DOD); Patent & Trademark Office (PTO); SENATE

Bills named: H.R. 2209 (116th)

Budget/Appropriations BUD

___ H.R. 21: Consolidated Appropriations Act, 2019 - FDA provisions related to prescription drugs ___ H.R. 265: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019 - FDA provisions related to prescription drugs House ___ H.R. 648: Consolidated Appropriations Act, 2019 - FDA provisions related to prescription drugs ___ H.R. 2500: National Defense Authorization Act for Fiscal Year 2020 - DoD provisions related to prescription drugs ___ H.R. 2740: Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020 - HHS provisions related to prescription drugs ___ H.R. 2745: Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2020 - VA Provisions related to prescription drugs ___ H.R. 2968: Department of Defense Appropriations Act, 2020 - DoD provisions related to prescription drugs ___ H.R. 3055: Making appropriations for the Departments of Commerce and Justice, Science, and Related Agencies for the fiscal year ending September 30, 2020, and for other purposes - FDA provisions related to prescription drugs ___ H.R. 3164: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 - FDA provisions related to prescription drugs _H.R. 3877 Bipartisan Budget Act of 2019 ___ H.R. 4378: Continuing Appropriations Act, 2020, and Health Extenders Act of 2019 - Provisions related to Medicare funding ___ H. Res. 28: Providing for consideration of the bill (H.R. 264) making appropriations for financial services and general government for the fiscal year ending September 30, 2019, and for other purposes; providing for consideration of the bill (H.R. 265) making appropriations for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies programs for the fiscal year ending September 30, 2019, and for other purposes; providing for consideration of the bill (H.R. 266) making appropriations for the Department of the Interior, environment, and related agencies for the fiscal year ending September 30, 2019, and for other purposes; providing for consideration of the bill (H.R. 267) making appropriations for the Department of Transportation, and Housing and Urban Development, and related agencies for the fiscal year ending September 30, 2019, and for other purposes; and waiving a requirement of clause 6(a) of rule XIII with respect to consideration of certain resolutions reported from the Committee on Rules. ___ H. Res. 293: Providing for budget enforcement for fiscal year 2020 ___ H. Res. 436: Providing for further consideration of the bill (H.R. 2740) making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2020, and for other purposes ___ H. Res. 4455: Providing for consideration of the bill (H.R. 3055) making appropriations for the Departments of Commerce and Justice, Science, and Related Agencies for the fiscal year ending September 30, 2020, and for other purposes; relating to consideration of the bill (H.R. 2740) making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2020, and for other purposes; and providing for proceedings during the period from June 28, 2019, through July 8, 2019 ___ S. 1215: National Defense Authorization Act for Fiscal Year 2020 - DoD provisions related to prescription drugs ___ S. 1790: National Defense Authorization Act for Fiscal Year 2020 - DoD provisions related to prescription drugs ___ S. 2474: Department of Defense Appropriations Act, 2020 - DoD provisions related to prescription drugs ___ S. 2522: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 - FDA provisions related to prescription drugs ___ S. ___: Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2020, and for other purposes

Contacted: Patent & Trademark Office (PTO); Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR); Defense, Dept of (DOD); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: S. 2522 (116th), H.R. 21 (116th), H.Res. 4455 (116th), H.R. 2740 (116th), H.R. 2745 (116th), S. 1790 (116th), H.Res. 28 (116th), H.R. 2968 (116th), H.R. 264 (116th), H.R. 3055 (116th), H.Res. 293 (116th), H.R. 648 (116th), H.R. 265 (116th), S. 1215 (116th), H.R. 3164 (116th), S. 2474 (116th), H.R. 266 (116th), H.R. 4378 (116th), H.R. 2500 (116th), H.R. 267 (116th), H.Res. 436 (116th)